Prediction of Atrial Fibrillation Using Polygenic Risk Score
The goal of this clinical trial is to learn whether a genetic risk score can help identify undiagnosed atrial fibrillation (AF) in adults who may have it. AF is an irregular heartbeat that raises the risk of stroke if not treated early. The main questions it aims to answer are: Can a polygenic risk score (PRS) - a scor
| Condition(s) | Atrial Fibrillation (AF) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to learn whether a genetic risk score can help identify undiagnosed atrial fibrillation (AF) in adults who may have it. AF is an irregular heartbeat that raises the risk of stroke if not treated early. The main questions it aims to answer are: Can a polygenic risk score (PRS) - a score based on a person's genes - identify who is more likely to have AF? Does combining PRS with a person's medical history predict AF better than using medical history alone? Participants will: Wear a continuous ECG patch for 7 days to record heart rhythm Give a blood sample for genetic testing to calculate their PRS Use a six-lead handheld ECG device (HATIV® P30, VUNO Inc., Seoul, Republic of Korea) to check their own heart rhythm at home once or twice a week for 1 year Visit |
| Who can participate | Inclusion Criteria: * Patients with symptoms suggestive of paroxysmal atrial fibrillation, such as intermittent palpitations or chest discomfort * Asymptomatic patients aged 60 or older with at least one of the following risk factors for atrial fibrillation: hypertension, diabetes, coronary artery disease, valvular heart disease, cardiomyopathy, sleep apnea, hyperthyroidism, obesity (BMI greater than 30), or chronic alcohol dependence (drinking more than 3 times per week) Exclusion Criteria: * Age under 20 years or over 80 years * Moderate or severe cognitive impairment * Previously diagnosed with atrial fibrillation prior to study enrollment * Does not consent to participate in the study |
| Ages | 20 Years to 79 Years |
| Sex | All |
| Lead sponsor | Seoul St. Mary's Hospital |
| Locations | Incheon, South Korea; Seoul, South Korea; Seoul, South Korea; Suwon, South Korea; Uijeongbu-si, South Korea |
| Start date | 2024-11-19 |
| NCT ID | NCT07641582 |
| Official listing | https://clinicaltrials.gov/study/NCT07641582 |